|Bid||34.69 x 900|
|Ask||34.71 x 2200|
|Day's range||32.88 - 34.78|
|52-week range||22.65 - 54.60|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||N/A|
|Earnings date||01 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||62.71|
Last week, you might have seen that FibroGen, Inc. (NASDAQ:FGEN) released its annual result to the market. The early...
FibroGen (FGEN) delivered earnings and revenue surprises of -80.65% and -74.01%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
FibroGen (FGEN) delivered earnings and revenue surprises of 3.39% and 8.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
If you own shares in FibroGen, Inc. (NASDAQ:FGEN) then it's worth thinking about how it contributes to the volatility...
Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock
Profitability analysis is one of the best ways to evaluate the prospects of a company. It is used in detecting a profitable company over a loss-making one.
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.